SIGA TECHNOLOGIES INC (SIGAQ:OTCBB)

SIGA Technologies is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX® (USAN tecovirimat, ST-246®), an orally administered antiviral drug that targets orthopoxvirus infections. TPOXX has been approved by the FDA for the treatment of human smallpox disease. It is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield.

Yearly		Quarterly
FYE 12/31 Quarter Ended 9/30/20 Quarter Ended 9/30/19 (in thousands, except per share amounts) Net Revenues 44,261 8,111 Net Income (Loss) 24,188 (1,206) Net Income Per Share 0.31 (0.03)

Company Contact:
Name:	JAY VOSLER
Title:
Phone:	(212) 672-9107

Print